90+ years of empowering people with severe diseases to live their best lives
For over 90 years, UCB has been at the forefront of scientific innovation, committed to improving the lives of people with severe immunological and neurological diseases. Our legacy of breakthroughs in neurology, particularly in epilepsy, and advancements in rheumatology underscores our resolve to help patients overcome the challenges of living with severe diseases like rheumatoid arthritis and psoriasis.
Leveraging leading-edge science and digital technology, we're determined to continue launching transformative medicines, enhancing patient care in severe diseases and securing a healthier future for all.
Here at UCB Canada, we reflect the same dedication to advancing our mission with care, precision and a vision that strives for the extraordinary.
The power to make a difference
UCB stands as a dynamic global biopharma leader specializing in neurology and immunology. With total revenues achieving €5.3 billion in 2023 and a dedicated workforce of over 9,000 employees worldwide, we are inspired by patients and driven by science. We combine biology and chemistry, using both large, antibody-based molecules and small chemical compounds to develop groundbreaking therapies for severe diseases.
UCB forges strategic alliances with other top pharmaceutical industry leaders, recognizing the multifaceted challenges of severe diseases that require collective expertise. Through collaboration, we maximize our strengths and engage with partners that offer additional or complementary capabilities, amplifying our success in providing transformative and sustainable healthcare solutions.
